title: [Efficacy and toxicity of FOLFOX6 regimen in treating colorectal cancer patients with liver metastasis].
abstract: OBJECTIVE
  FOLFOX6 regimen has been used in treating advanced colorectal cancer for a period, but there is no systemic study on FOLFOX6 regimen in treating Chinese colorectal cancer patients with liver metastasis. This study was to evaluate the efficacy of FOLFOX6 regimen on Chinese colorectal cancer patients with liver metastasis, and observe the adverse events.
  
  
  METHODS
  Ninety-one colorectal cancer patients with liver metastasis were treated by FOLFOX6 regimen. FOLFOX6 regimen consisted of 2-hour infusion of oxaliplatin (100 mg/m(2)) and 2-hour infusion of leucovorin (CF) (400 mg/m(2)) on Day l, followed by 5-fluorouracil (5-FU) bolus (400 mg/m(2)) on Day 1 and 46-hour infusion (2.4 g/m(2)). FOLFOX6 regimen was repeated at 2-week intervals. The clinical efficacy and adverse events were evaluated.
  
  
  RESULTS
  The objective response rate for all patients was 40.7%, with 4 cases of complete remission (CR), 33 partial remission (PR), 19 stable disease (SD), and 35 progressive disease (PD). There was no significant difference in objective response rate between the patients with and without previous treatment (P>0.05). The median survival time was 17.0 months for all patients, 20.0 months for the patients without previous treatment, and 12.0 months for the patients with previous treatment. The time to progress (TTP) was 7.0 months for all patients, 9.0 months for the patients without previous treatment, and 6.0 months for the patients with previous treatment. Peripheral neuritis, gastrointestinal reaction, and myelosuppression were major adverse events. All patients with 5-FU-associated adverse events recovered after treatment.
  
  
  CONCLUSIONS
  FOLFOX6 regimen can be used in treating colorectal cancer with liver metastasis for its efficacy and less toxicity.
authors: State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, P. R. China.
authors: Guo-Qiang
authors: GQ
authors: Wang
authors: De-Sen
authors: DS
authors: Wan
authors: Zhi-Wei
authors: ZW
authors: Zhou
authors: Zhi-Zhong
authors: ZZ
authors: Pan
authors: Gong
authors: G
authors: Chen
authors: Zhen-Hai
authors: ZH
authors: Lu
authors: Yu-Jing
authors: YJ
authors: Fang
authors: Xiao-Jun
authors: XJ
authors: Wu
authors: Li-Ren
authors: LR
authors: Li
authors: Pei-Rong
authors: PR
authors: Ding
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009443:Neuritis / Q000139:chemically induced; D009944:Organoplatinum Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D000077150:Oxaliplatin; D012004:Rectal Neoplasms / Q000188:drug therapy / Q000473:pathology; D012074:Remission Induction; D015996:Survival Rate; D055815:Young Adult
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D005472:Fluorouracil